Connor, Clark & Lunn Investment Management Ltd. Anavex Life Sciences Corp. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $21.8 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$8.9 - $12.86 $712,044 - $1.03 Million
80,005 Added 472.79%
96,927 $1 Million
Q2 2022

Aug 05, 2022
BUY
$7.31 - $12.84 $123,699 - $217,278
16,922 New
16,922 $169,000

Others Institutions Holding AVXL

# of Institutions
159
Shares Held
31.6M
Call Options Held
910K
Put Options Held
1.35M
View Full List

About ANAVEX LIFE SCIENCES CORP.

AVXL Quotes by TradingView
  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $352M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email